Why the study?
Despite concerns about heparin-induced hemorrhagic pericarditis and cardiac tamponade, alertness regarding this complication and current anticoagulation recommendations in dialysis-associated pericarditis required highlighting.
Does heparin increase the risk of hemorrhagic pericarditis and cardiac tamponade in patients with dialysis-associated pericarditis and new-onset atrial fibrillation?
Does heparin increase the risk of hemorrhagic pericarditis and cardiac tamponade in patients with dialysis-associated pericarditis and new-onset atrial fibrillation?
This case highlights the potential risk of hemorrhagic conversion of dialysis-associated pericarditis when initiating heparin for new-onset atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Urges caution with heparin for new AF in dialysis pericarditis; leaves open causal link to hemorrhagic tamponade.
Heparin is a preferred initial anticoagulant in patients with new-onset atrial fibrillation (AF). Despite continuous debate about the risk, there has been a concern about heparin-induced hemorrhagic pericarditis and cardiac tamponade. We present a case of a new onset atrial fibrillation (AF) in a patient with renal impairment and evidence of pericardial effusion complicated by hemopericardium development after starting anticoagulation. Although the risk of hemorrhagic conversion of uremic pericarditis induced by heparin in ESRD patients with new onset AF was suggested in the literature, this case raises the possibility of a similar complication in dialysis-associated pericarditis. Therefore, we aim to heighten alertness regarding this potential complication of a commonly used medication in clinical practice. We also aim to review the current anticoagulation recommendations in this setting.
No takes yet. Share an insight, caveat, or question.
Abu-Abaa et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: